Evidence map›Paper›PMID 40882022›Full record

ArticleCancer research2025

Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche.

James B Reinecke, Leyre Jimenez Garcia, Amanda J Saraf, John Hinckley, Amy C Gross, Helene Le Pommellet, Kelly M Gutpell, Maren Cam, Matthew V Cannon, Matthew J Gust and 4 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

James B ReineckeDepartment of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0002-6498-7479
Leyre Jimenez GarciaCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0009-0006-7281-1381
Amanda J SarafDepartment of Hematology, Oncology, and Bone Marrow Transplant, Riley Children's Hospital, Indianapolis, Indiana.ORCID 0000-0002-0167-8716
John HinckleyBattelle, Columbus, Ohio.ORCID 0000-0002-3479-1723
Amy C GrossCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0002-0123-5085
Helene Le PommelletThe Ohio State University College of Veterinary Medicine, Columbus, Ohio.ORCID 0000-0003-0534-338X
Kelly M GutpellDepartment of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0003-4808-0655
Maren CamInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0002-6337-6414
Matthew V CannonCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0002-3035-9490
Matthew J GustCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0009-0009-3159-2559
Sophia VatelleCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0009-0004-6260-8465
Berkley E GryderDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.ORCID 0000-0003-0130-2302
Ruben DriesSection of Hematology and Medical Oncology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts.ORCID 0000-0001-7650-7754
Ryan D RobertsDepartment of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0001-5028-744X

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Targeting cooperative mechanisms of metastatic colonization in osteosarcomaR01CA260178 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RYAN D. ROBERTS · 2022 to 2026
$2.2M
Elucidating and exploiting the mechanisms by which IL-6 and IL-8 facilitate osteosarcoma metastasisK08CA201638 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI ROBERTS, RYAN D. · 2016 to 2020
$815k
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcomaK01OD031811 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAVIES, ALEXANDER E · 2021 to 2025
$599k
Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)Animal Cancer Foundation (ACF)CancerFree KIDS (CFK)MIB Agents (Mib Agents Inc.)National Cancer Institute (NCI) K08CA201638National Cancer Institute (NCI) R01CA260178National Cancer Institute (NCI) UL1TR002733NCATS NIH HHS UL1 TR002733NCI NIH HHS K08 CA201638NCI NIH HHS R01 CA260178NIH HHS K01 OD031811Osteosarcoma Institute (OSI)Sarcoma Foundation of America (SFA)St. Baldrick's Foundation (SBF)Steps for Sarcoma
6 · The paper itself

Abstract

Osteosarcoma is an aggressive and deadly bone tumor, primarily afflicting children, adolescents, and young adults. Poor outcomes for patients with osteosarcoma are intricately linked with the development of lung metastasis, which is responsible for nearly all deaths caused by osteosarcoma. Identification of the underlying cellular and molecular mechanisms that govern the metastatic colonization of circulating tumor cells to the lung is needed to develop biologically defined, metastasis-targeting therapies. In this study, using a combination of an in vitro organotypic metastasis model, single-cell RNA sequencing, human xenograft models, and murine immunocompetent osteosarcoma models, we found that metastasis is initiated by a subpopulation of hypoproliferative cells with the unique capacity to sustain the production of metastasis-promoting cytokines, such as IL6 and CXCL8, in response to lung epithelial cell-derived IL1α. Critically, genomic and pharmacologic disruption of IL1 signaling in osteosarcoma cells significantly reduced metastatic progression. Collectively, this study shows that tumor-stromal interactions are important for metastasis and suggests that metastatic competency is driven in part by the ability of tumor cells to respond to cues from the metastatic niche. Disruption of tumor-stromal signaling is a promising therapeutic approach to interrupt metastasis progression. SIGNIFICANCE: Elucidation of key traits of metastasis-competent cancer cells identified cross-talk between osteosarcoma and lung epithelial cells that mediates metastasis and revealed IL1 inhibition as a promising therapeutic strategy for blocking metastasis.

Indexed as

Interleukin 1 Receptor Antagonist ProteinInterleukinsLung NeoplasmsNeoplasm MetastasisOsteosarcomaAnimalsCell Line, TumorChemotaxisFemaleHumansInterleukin-1alphaInterleukin-6Interleukin-8MiceMice, KnockoutXenograft Model Antitumor AssaysCXCL8 protein, humanIL1A protein, humanIL6 protein, humanInterleukin-1alphaInterleukin 1 Receptor Antagonist ProteinInterleukin-6Interleukin-8Interleukins

Identifiers

PMID40882022
PMCPMC12616249

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.